Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 2
2001 1
2006 1
2007 1
2010 1
2011 3
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 2
2019 3
2020 2
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W, Jiang Q, Zhou Y. Liu W, et al. Chin Clin Oncol. 2018 Aug;7(4):42. doi: 10.21037/cco.2018.08.02. Chin Clin Oncol. 2018. PMID: 30173532 Free article. Review.
There is more emerging evidence of different sensitivity to treatment for different histological subtypes, second-line treatment for advanced sarcoma is being increasingly driven by histology. Cytotoxic drugs such as dacarbazine, gemcitabine, and taxanes have shown …
There is more emerging evidence of different sensitivity to treatment for different histological subtypes, second-line treatment for adva …
Maintenance therapy and drug holiday in sarcoma patients: systematic review.
Lebellec L, Defachelles AS, Cren PY, Penel N. Lebellec L, et al. Acta Oncol. 2020 Sep;59(9):1084-1090. doi: 10.1080/0284186X.2020.1759825. Epub 2020 May 13. Acta Oncol. 2020. PMID: 32400254
Purpose: Overall prognosis of advanced sarcoma remains poor, optimization of systemic treatment is urgently needed in this setting.Materials and methods: We systematically reviewed fully published English-speaking literature about maintenance therapy and drug holida …
Purpose: Overall prognosis of advanced sarcoma remains poor, optimization of systemic treatment is urgently needed in this set …
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.
Gordon EM, Angel NL, Omelchenko N, Chua-Alcala VS, Moradkhani A, Quon D, Wong S. Gordon EM, et al. Anticancer Res. 2023 May;43(5):1993-2002. doi: 10.21873/anticanres.16360. Anticancer Res. 2023. PMID: 37097693 Clinical Trial.
BACKGROUND/AIM: Advanced sarcoma has a poor prognosis. Dysregulation of the mammalian target of rapamycin (mTOR) occurs in various types of cancer. ...PATIENTS AND METHODS: Previously treated patients 18 years with confirmed diagnosis of advanced sarcoma …
BACKGROUND/AIM: Advanced sarcoma has a poor prognosis. Dysregulation of the mammalian target of rapamycin (mTOR) occurs in var …
The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW, Desai J. Ryan CW, et al. Am Soc Clin Oncol Educ Book. 2013. doi: 10.14694/EdBook_AM.2013.33.e386. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714556 Free article. Review.
Among the latter, pazopanib demonstrated a progression-free survival over placebo in prior-treated patients with advanced sarcoma, and is now approved for use in the sarcomas in many countries. ...
Among the latter, pazopanib demonstrated a progression-free survival over placebo in prior-treated patients with advanced sarcoma …
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F, D'Ambrosio L, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, Rulli E, Comandini D, Palmerini E, Baldi GG, DeCensi A, Bergaglio M, Marra D, Marchesi E, Siri G, D'Incalci M, Grignani G. Grosso F, et al. Cancer. 2020 Nov 1;126(21):4726-4734. doi: 10.1002/cncr.33120. Epub 2020 Aug 4. Cancer. 2020. PMID: 32749681 Free article. Clinical Trial.
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Carmagnani Pestana R, et al. Clin Cancer Res. 2023 May 1;29(9):1708-1718. doi: 10.1158/1078-0432.CCR-22-3629. Clin Cancer Res. 2023. PMID: 37058010 Free PMC article.
This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes for patients with advanced sarcoma. EXPERIMENTAL DESIGN: In this retrospective analysis, investigational treatment characteristics and longit …
This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes for patients wi …
Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: Are Indian patients different?
Sharma A, Vanidassane I, Aggarwal A, Mridha AR, Pandey R, Dhamija E, Barwad A, Rastogi S. Sharma A, et al. Indian J Cancer. 2019 Jul-Sep;56(3):207-210. doi: 10.4103/ijc.IJC_105_18. Indian J Cancer. 2019. PMID: 31389382 Free article. Clinical Trial.
PURPOSE: There is no study till date determining the spectrum of adverse events of pazopanib in Indian patients with advanced sarcoma. MATERIALS AND METHODS: We conducted a retrospective study by analyzing the case records of metastatic sarcoma patients treated with …
PURPOSE: There is no study till date determining the spectrum of adverse events of pazopanib in Indian patients with advanced sarc …
The changing landscape of phase II/III metastatic sarcoma clinical trials-analysis of ClinicalTrials.gov.
Que Y, Xiao W, Xu BS, Wen XZ, Weng DS, Zhang X. Que Y, et al. BMC Cancer. 2018 Dec 13;18(1):1251. doi: 10.1186/s12885-018-5163-2. BMC Cancer. 2018. PMID: 30545340 Free PMC article.
This study aimed to provide a comprehensive landscape of the characteristics of metastatic or advanced sarcoma clinical trials using the substantial resource of the ClincialTrials.gov database. ...These findings emphasize the desperate need for novel strategies, inc …
This study aimed to provide a comprehensive landscape of the characteristics of metastatic or advanced sarcoma clinical trials …
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.
Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA. Rouleau C, et al. Int J Oncol. 2011 Jul;39(1):73-89. doi: 10.3892/ijo.2011.1020. Epub 2011 Apr 29. Int J Oncol. 2011. PMID: 21537839
These data provide clinical and preclinical evidence that endosialin can be detected in advanced sarcoma. These results demonstrate for the first time that endosialin is a suitable therapeutic target for poor prognosis and advanced disease....
These data provide clinical and preclinical evidence that endosialin can be detected in advanced sarcoma. These results demons …
'When something is this rare … how do you know bad really is bad…?'-views on prognostic discussions from patients with advanced soft tissue sarcoma.
Gough N, Ross JR, Riley J, Judson I, Koffman J. Gough N, et al. BMJ Support Palliat Care. 2019 Mar;9(1):100-107. doi: 10.1136/bmjspcare-2015-000898. Epub 2015 Dec 28. BMJ Support Palliat Care. 2019. PMID: 26715566
RESULTS: All participants understood the incurable nature of advanced sarcoma. However, prognostic discussions were rare, always patient initiated and did not include known survival data, despite direct participant enquiry. ...
RESULTS: All participants understood the incurable nature of advanced sarcoma. However, prognostic discussions were rare, alwa …
26 results